How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- ACLX
- JNJ
Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.